Monitoring cardiac function in patients receiving doxorubicin

Seminars in Nuclear Medicine

Volumn 35, Issue 3 SPEC. ISS., 2005, Pages 197-201

  Lu, Ping ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOCHEMICAL MARKER; CARDIOTOXIN; DOXORUBICIN; EPIRUBICIN; IRON CHELATING AGENT; MONOCLONAL ANTIBODY; MYOSIN ANTIBODY IN 111; PACLITAXEL; RADIOISOTOPE; RAZOXANE; TRASTUZUMAB;

ARTICLE; CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL DAMAGE; CONGESTIVE HEART FAILURE; DRUG UPTAKE; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HUMAN; MUSCLE CELL; NONHUMAN; PATIENT MONITORING; SCINTIANGIOCARDIOGRAPHY;

EID: 23744457621     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2005.02.005     Document Type: Review

References (51)

1. Anticancer drugs R.A. Harvey P.C. Champe Lippincott's Illustrated Reviews Pharmacology 1992 JB Lippincott Company Philadelphia
2. O.J. Arola, A. Saraste, K. Pulkki Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis Cancer Res 60 2000 1789 1792
3. T. Nakamura, Y. Ueda, Y. Juan Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats In vivo study Circulation 102 2000 572 578
4. B.A. Khaw, J. Silva Da, A. Petrov Indium 111 antimyosin and Tc-99m glucaric acid for noninvasive identification of oncotic and apoptotic myocardial necrosis J Nucl Cardiol 9 2002 471 481
5. D.D. Von Hoff, M.W. Layard, P. Basa Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 1979 710 717
6. S.M. Swain, F.S. Whaley, M.S. Ewer Congestive heart failure in patients treated with doxorubicin a retrospective analysis of three trials Cancer 97 2003 2869 2879
7. K. Shan, A.M. Lincoff, J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1996 47 58
8. L.J. Steinherz, P.G. Steinherz, C.T. Tan Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1991 1672 1677
9. S.E. Lipshultz, S.D. Colan, R.D. Gelber Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 342 1991 808 815
10. O. Hequet, Q.H. Le, I. Mouller Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults J Clin Oncol 22 2004 1864 1870
11. B.V. Jensen, T. Skovsgaard, S.L. Nielsen Functional monitoring of anthracycline cardiotoxicity A prospective, blinded, long-term observational study of outcome in 120 patients Ann J Oncol 13 2002 699 709
12. N. Van Royen, C.C. Jaffe, H.M. Krumholz Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions Am J Cardiol 77 1996 843:850
13. T. Nousiainen, E. Vanninen, E. Jantunen Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy J Intern Med 249 2001 297 303
14. J. Alexander, N. Dainiak, H.J. Berger Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography N Engl J Med 300 1979 278 283
15. M.S. Piver, D.L. Marchetti, K.L. Parthasarathy Doxorubicin hydrochloride (Adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography Cancer 56 1985 76 80
16. R.G. Schwartz, W.B. McKenzie, J. Alexander Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy seven-year experience using serial radionuclide angiocardiography Am J Med 82 1987 1109 1118
17. I. Mitani, D. Jain, T.M. Joska Doxorubicin cardiotoxicity prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era J Nucl Cardiol 10 2003 132 139
18. T. Nousiainen, E. Jantunen, E. Vanninen Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients Br J Cancer 86 2002 1697 1700
19. L.J. Steinherz, T. Graham, R. Hurwitz Guidelines for cardiac monitoring of children during and after anthracycline therapy Report of the cardiology committee of the children's cancer study group Pediatrics 89 1992 942 949
20. J.H. McKillop, M.R. Bristow, M.L. Goris Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity Am Heart J 106 1983 1048 1056
21. S.T. Palmeri, R.O. Bonow, C.E. Myers Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography Am J Cardiol 58 1986 607 613
22. B.H. Lee, L.S. Goodenday, G.J. Muswick Alterations in left ventricular diastolic function with doxorubicin therapy J Am Coll Cardiol 9 1987 184 188
23. W.I. Ganz, K.S. Sridhar, T.J. Forness Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate Am J Clin Oncol 16 1993 109 112
24. Y. Cottin, C. Touzery, B. Coudert Impairment of diastolic function during short-term anthracycline chemotherapy Br Heart J 73 1995 61 64
25. I.P. Clements, B.J. Davis, G.A. Wiseman Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy Significance of gender and concurrent mediastinal radiation Nucl Med Commun 23 2002 521 527
26. R.A. Valdes Olmos, I. Carrio, C.A. Hoefnagel High sensitivity of radiolabeled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction Nucl Med Commun 23 2002 871 877
27. M. Hiroe, Y. Ohta, N. Fujita Myocardial uptake of In-111 monoclonal antimyosin Fab in detecting doxorubicin cardiotoxicity in rats Morphological and hemodynamic findings Circulation 86 1992 1965 1972
28. M. Estorch, I. Carrio, L. Berna Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer J Nucl Med 31 1990 1965 1969
29. I. Carrio, A. Lopez-Pousa, M. Estorch Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies J Nucl Med 34 1993 1503 1507
30. L.C.M. Kremer, M.M.C. Tiel-van Buul, M.C. Ubbink Indium-111-antimyosin scintigraphy in the early detection of heart damage after anthracycline therapy in children J Clin Oncol 17 1999 1208 1211
31. C.L. Maini, R. Sciuto, A. Ferraironi Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity J Nucl Cardiol 4 1997 502 508
32. S. Wakasugi, A. Wada, Y. Hasegawa Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine J Nucl Med 33 1992 208 214
33. R.A. Valdes Olmos, W.W. Ten Bokkel Huinink, J.C. Greve I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity Clin Nucl Med 17 1992 163 167
34. Carrio I, Estorch M, Berna L,, et al. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 36:2044-2049
35. Lekakis, V. Prassopoulos, P. Athanassiadis Doxorubicin-induced cardiac neurotoxicity study with iodine 123-labeled metaiodobenzylguanidine scintigraphy J Nucl Cardiol 3 1996 37 41
36. H. Takano, H. Ozawa, I. Kobayashi Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy J Cardiol 27 1996 49 55
37. F. Blankenberg, C. Mari, H.W. Strauss Imaging cell death in vivo Q J Nucl Med 47 2003 337 348
38. R.J. Bennink, M.J. van den Hoff, F.J. van Hemert Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats J Nucl Med 45 2004 842 848
39. S.E. Lipshultz, N. Rifai, S.E. Sallan Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury Circulation 96 1997 2641 2648
40. E.H. Herman, J. Zhang, S.E. Lipshultz Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin J Clin Oncol 17 1999 2237 2243
41. H.W. Auner, C. Tinchon, W. Linkesch Prolonged monitory of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies Ann Hematol 82 2003 218 222
42. E. Koh, T. Nakamura, H. Takahashi Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats Circ J 68 2004 163 167
43. D. Cardinale, M.T. Sandri, A. Colombo Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
44. P. Mathew, W. Suarez, K. Kip Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study Cancer Invest 19 2001 352 359
45. E. Kismet, A. Varan, C. Ayabakan Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin Pediatr Blood Cancer 42 2004 220 224
46. T.A. McDonagh, A.D. Cunningham, C.E. Morrison Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population Heart 86 2001 21 26
47. T. Suzubi, D. Hayashi, T. Yamarak Elevated B-type natriuretic peptide levels after anthracycline administration Am Heart J 136 1998 362 363
48. T. Nousianinen, E. Jantunen, E. Vanninen Natriuretic peptide as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma Eur J Haehmatol 62 1999 135 141
49. Meinardi MT, van Veldhuisen DJ, Gietema JA,, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol 19:2746-2753
50. M. Theodoulou, C. Hudis Cardiac profiles of liposomal anthracyclines Cancer 100 2004 2052 2063
51. S.M. Swain, P. Vici The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment Expert panel review J Cancer Res Clin Oncol 130 2004 1 7